Abstract
Background
The clinical spectrum of COVID-19 is variable and ranges from asymptomatic, mildly symptomatic, moderately severe and severe disease. A small proportion might develop severe disease and may have cytokine storm. One of the therapeutic options to treat such cases is Tocilizumab (TCZ). In this study, we present cases of severe COVID-19 treated with TCZ and glucocorticoids and discuss the treatment responses.
Methods
This is a retrospective observational study of severe COVID-19 cases treated with TCZ and glucocorticoids. The case series examined the characteristics and outcome of those patients.
Results
This study included 40 Severe Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) confirmed patients who received TCZ and glucocorticoids. The mean age of the included patients was 57.55 (±Standard deviation 12.86) years. There were 34 (85%) males, 19 (47.5%) were obese (BMI >30), 13 (32.5%) over weight, and five (12.5%) normal weight. The mean days from positive SARS-CoV-2 polymerase chain reaction (PCR) test to admission was 1.641 (±3.2) days. Of the patients, 18 (45%) had diabetes mellitus, 14 (35%) had hypertension. The mean days from hospital admission to ICU was 1.8 (±2.6), 20 (50%) required mechanical ventilation, 39 (97.5%) had received prone position, seven (17.5%) had renal replacement therapy, 13 (32.5%) required inotropes, four (10%) had plasmapheresis, one (2.5%) had intravenous immunoglobulin, all patients received steroid therapy, and the majority 31 (77.5%) did not receive any anti-viral therapy. Of all the patients, six (15%) died, 28 (70%) were discharged and six (15%) were still in hospital.
Conclusion
The overall mortality rate was lower than those cited in meta-analysis. As our understanding of the COVID-19 continues, the approach and therapeutics are also evolving.
Article PDF
Avoid common mistakes on your manuscript.
References
Al-Tawfiq JA, Al-Yami SS, Rigamonti D. Changes in healthcare managing COVID and non–COVID-19 patients during the pandemic: striking the balance. Diagn Microbiol Infect Dis 2020;98;115147.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395; 1054–62.
Nicastri E, D’Abramo A, Faggioni G, De Santis R, Mariano A, Lepore L, et al. Coronavirus disease (COVID-19) in a paucisymptomatic patient: epidemiological and clinical challenge in settings with limited community transmission, Italy, February 2020. Euro Surveill 2020;25;2000230.
Al-Omari A, Alhuqbani WN, Zaidi ARZ, Al-Subaie MF, AlHindi AM, Abogosh AK, et al. Clinical characteristics of non-intensive care unit COVID-19 patients in Saudi Arabia: a descriptive cross-sectional study. J Infect Public Health 2020;13;1639–44.
Al Mutair A, Alhumaid S, Alhuqbani WN, Zaidi ARZ, Alkoraisi S, Al-Subaie MF, et al. Clinical, epidemiological, and laboratory characteristics of mild-to-moderate COVID-19 patients in Saudi Arabia: an observational cohort study. Eur J Med Res 2020;25;61.
AlJishi JM, Alhajjaj AH, Alkhabbaz FL, AlAbduljabar TH, Alsaif A, Alsaif H, et al. Clinical characteristics of asymptomatic and symptomatic COVID-19 patients in the Eastern Province of Saudi Arabia. J Infect Public Health 2021;14;6–11.
Tirupathi R, Muradova V, Shekhar R, Salim SA, Al-Tawfiq JA, Palabindala V. COVID-19 disparity among racial and ethnic minorities in the US: a cross sectional analysis. Travel Med Infect Dis 2020;38;101904.
Al-Tawfiq JA, Leonardi R, Fasoli G, Rigamonti D. Prevalence and fatality rates of COVID-19: what are the reasons for the wide variations worldwide? Travel Med Infect Dis 2020;35;101711.
Al-Tawfiq JA, Sattar A, Al-Khadra H, Al-Qahtani S, Al-Mulhim M, Al-Omoush O, et al. Incidence of COVID-19 among returning travelers in quarantine facilities: a longitudinal study and lessons learned. Travel Med Infect Dis 2020;38;101901.
Al-Tawfiq JA, Hinedi K. The calm before the storm: clinical observations of Middle East respiratory syndrome (MERS) patients. J Chemother 2018;30;179–82.
Siddiqi HK, Mehra MR. COVID-19 illness in native and immu-nosuppressed states: a clinical–therapeutic staging proposal. J Hear Lung Transplant 2020;39;405–7.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395;497–506.
Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest 2020;130;2202–5.
Tirupathi R, Bharathidasan K, Areti S, Kaur J, Salim S, Al-Tawfiq JA. The shortcomings of tocilizumab in COVID-19. Infez Med 2020;28;465–8.
Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents 2020;55;105954.
Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol 2020;38;529–32.
Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A 2020;117;10970–5.
Radbel J, Narayanan N, Bhatt PJ. Use of tocilizumab for COVID-19-induced cytokine release syndrome: a cautionary case report. Chest 2020;158;e15–e19.
Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 2020;92; 814–18.
Zhang S, Li L, Shen A, Chen Y, Qi Z. Rational use of tocilizumab in the treatment of novel coronavirus pneumonia. Clin Drug Investig 2020;40;511–18.
(Released by National Health Commission & National Administration of Traditional Chinese Medicine on March 3, 2020). Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial version 7). Chin Med J (Engl) 2020;133;1087–95.
AlJishi JM, Al-Tawfiq JA. Intermittent viral shedding in respiratory samples of patients with SARS-CoV-2: observational analysis with infection control implications. J Hosp Infect 2020;107; 98–100.
Guisado-Vasco P, Valderas-Ortega S, Carralón-González MM, Roda-Santacruz A, González-Cortijo L, Sotres-Fernández G, et al. Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: a retrospective observational study (COQUIMA cohort). EClinicalMedicine 2020;28;100591.
Alsofayan YM, Althunayyan SM, Khan AA, Hakawi AM, Assiri AM. Clinical characteristics of COVID-19 in Saudi Arabia: a national retrospective study. J Infect Public Health 2020;13;920–5.
Barry M, AlMohaya AE, AlHijji A, Akkielah L, AlRajhi A, Almajid F, et al. Clinical characteristics and outcome of hospitalized COVID-19 patients in a MERS-CoV endemic area. J Epidemiol Glob Health 2020;10;214–21.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323;1061–9.
Hassoun A, Thottacherry ED, Muklewicz J, Aziz QUA, Edwards J. Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19. J Clin Virol 2020;128;104443.
Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med 2020;383;2333–44.
Wang Y, Lu X, Li Y, Chen H, Chen T, Su N, et al. Clinical course and outcomes of 344 intensive care patients with COVID-19. Am J Respir Crit Care Med 2020;201;1430–4.
Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020;369;m1966.
Fomina DS, Lysenko MA, Beloglazova IP, Mutovina ZY, Poteshkina NG, Samsonova IV, et al. Temporal clinical and laboratory response to interleukin-6 receptor blockade with tocilizumab in 89 hospitalized patients with COVID-19 pneumonia. Pathog Immun 2020;5;327–41.
Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med 2021;181;32–40.
Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med 2021;181;41–51.
Rossi B, Nguyen LS, Zimmermann P, Boucenna F, Dubret L, Baucher L, et al. Effect of tocilizumab in hospitalized patients with severe COVID-19 pneumonia: a case-control cohort study. Pharmaceuticals (Basel) 2020;13;317.
Perrone F, Piccirillo MC, Ascierto PA, Salvarani C, Parrella R, Marata AM, et al. Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trial. medRxiv 2020;18;405.
Sigurgeirsson B, Steingrímsson Ó, Sveinsdóttir S. Prevalence of onychomycosis in Iceland: a population-based study. Acta Derm Venereol 2002;82;467–9.
Armstrong RA, Kane AD, Cook TM. Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies. Anaesthesia 2020;75;1340–9.
Quah P, Li A, Phua J. Mortality rates of patients with COVID-19 in the intensive care unit: a systematic review of the emerging literature. Crit Care 2020;24;285.
RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med 2020;NEJMoa2021436 [Online ahead of print].
Author information
Authors and Affiliations
Corresponding author
Additional information
Data availability statement: Data available upon request.
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
AlBahrani, S., Al-Tawfiq, J.A., Alshaer, A.R. et al. A Case Series of Severe Hospitalized COVID-19 Patients Treated with Tocilizumab and Glucocorticoids: A Report from Saudi Arabian Hospital. J Epidemiol Glob Health 11, 233–237 (2021). https://doi.org/10.2991/jegh.k.210112.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/jegh.k.210112.001